Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan results Journal Article
| Authors: | Morris, P. G.; Van Poznak, C.; Modi, S.; Mak, A. F.; Patil, S.; Larson, S.; Hudis, C. A.; Divgi, C.; Grewal, R. K. |
| Article Title: | Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan results |
| Abstract: | Introduction: Theoretically, the bisphosphonates used to treat metastatic bone disease could influence the results of nuclear bone scans which use the structurally similar technetium 99m methylene diphosphonate (99mTc MDP). A prospective clinical study was designed to explore this hypothesis. Patients and Methods: Patients with metastatic breast cancer receiving intravenous bisphosphonate (IVBP) therapy who had ≥3 osseous lesions on nuclear bone scan were eligible. A baseline bone scan (number 1) was performed as clinically indicated and IVBP with zoledronic acid was administered within 72 hours. A second bone scan (number 2) was performed within 72 hours of zoledronic acid dosing. Both bone scans were reviewed in a blinded fashion and assessed for changes in the number and intensity of osseous lesions. Ten patients were planned to yield at least 30 lesions. Results: Ten patients were enrolled. One patient withdrew consent and 1 was excluded due to protocol deviation. Among the 8 patients were 163 assessable osseous lesions. The median time from bone scan number 1 to IVBP was 1 day (range, 1-2 days). The median time from IVBP to bone scan number 2 was 2 days (range, 1-3 days). The paired imaging showed no changes in the total number of bone metastases. One hundred sixty-one lesions were identical in both scans; in 1 patient there were 2 lesions that were discordant, one more intense, the other less intense. Conclusion: These data do not support the hypothesis that IVBP therapy interferes with bone scan results. |
| Keywords: | adult; clinical article; aged; bone neoplasms; middle aged; clinical trial; bone metastasis; technetium 99m; prospective study; radiopharmaceuticals; metastasis; breast cancer; image analysis; clinical assessment; drug structure; drug effect; breast neoplasms; bone lesion; drug uptake; tumor burden; medronate technetium tc 99m; infusions, intravenous; diphosphonates; intraductal carcinoma; bone density conservation agents; jaw diseases; osteonecrosis; radionuclide imaging; bone scintiscanning; zoledronic acid; imidazoles; bone metastases; bisphosphonate; bone scanning; methylene diphosphonate; jaw; technetium tc 99m medronate |
| Journal Title: | Clinical Breast Cancer |
| Volume: | 10 |
| Issue: | 1 |
| ISSN: | 1526-8209 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2010-02-01 |
| Start Page: | 33 |
| End Page: | 39 |
| Language: | English |
| DOI: | 10.3816/CBC.2010.n.004 |
| PUBMED: | 20133256 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 1" - "Export Date: 20 April 2011" - "CODEN: CBCLB" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work